This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
DOK7 · Western blot design guide
DOK7 Western Blot Planning Guide
Plan a DOK7 Western blot around the catalog-observed 53.1 kDa band, image-backed A05165-1 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
DOK7 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 53.1 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Heart muscle | |
| Negative control | Adipose tissue |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 53.1 kDa |
| ⓘ | Localization | Cell membrane / Synapse |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated DOK7 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Heart muscle |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A05165-1 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected DOK7 Western Blot Band Size?
Use the product-observed 53.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 53.1 kDa | Matches the authoritative product WB observation. |
| 53.1 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected DOK7 appearancePlan around 53.1 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 53.1 kDa; use this as the primary experimental expectation. |
| Calculated mass | 53.1 kDa from UniProt Q18PE1; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A05165-1. |
| Situation | Likely cause | Next action |
|---|---|---|
| 53.1 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing DOK7 band
A05165-1 · DOK7
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for DOK7 Western blot
🧪Use Heart muscle as the first positive-control candidate and Adipose tissue as the HPA Not detected negative candidate.
Positive control: Heart muscle (High)
Negative control: Adipose tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for DOK7
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Heart muscle | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced DOK7 Western Blot Tips
Deeper troubleshooting and optimisation questions for DOK7, answered from its protein features.
Which band should guide the blot?
Use 53.1 kDa, the observation attached to the authoritative A05165-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 53.1 kDa expectation.
Which positive control should I start with?
Start with Heart muscle, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adipose tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for DOK7 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A05165-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
DOK7 Western Blot Reagents
Human/Mouse/Rat-reactive DOK7 Western blot reagents with authoritative product imagery.
Real WB data
Anti-DOK7 Antibody Picoband®
Cat # A05165-1
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q18PE1
- Human Protein Atlas — DOK7
- A05165-1 product record
- PMC10117378 — A mutation in DOK7 in congenital myasthenic syndrome forms aggresome in cultured cells, and reduces DOK7 expression and MuSK phosphorylation in patient-derived iPS cells (Human molecular genetics, 2023)
- PMC11258441 — Prevention of age-related neuromuscular junction degeneration in sarcopenia by low-magnitude high-frequency vibration (Aging cell, 2024)
- PMC8277574 — Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia (Nature, 2021)
